Drugs.com New Drug ApprovalsOriginal article
Xeomin Approved For Expanded Indication in Pediatric Upper Limb Spasticity Patients with Cerebral Palsy Following FDA Label Update
RegulatoryapprovedXeominPositive
AI Analysis
Summary
Merz Therapeutics announced FDA approval of a label expansion for Xeomin (incobotulinumtoxinA) to treat pediatric upper limb spasticity in cerebral palsy patients, broadening the drug's therapeutic indication.
Outcome Details
FDA approved label expansion for Xeomin in pediatric upper limb spasticity patients with cerebral palsy
Importance:7/10
Sentiment:
0.80
FDA approvallabel expansionpediatric indicationspasticitycerebral palsy
Read the original article
Published by Drugs.com New Drug Approvals on June 26, 2026 4:06 AM